Magle Chemoswed Holding
7.85 SEK
+0.64 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.64 %
-29.28 %
-55.40 %
-50.94 %
-60.75 %
-74.84 %
-68.73 %
-81.46 %
-60.93 %
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
162.1M SEK
Turnover
10.21K SEK
Revenue
236.04M
EBIT %
9.84 %
P/E
0.18
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27/3
2026
Annual report '25
18/5
2026
Interim report Q1'26
26/5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
Magle Group Issues Profit Warning Ahead of Q4 and Full-Year 2025 Results
Magle Group Announces Strategic Refocus to Strengthen Profitability and Operational Discipline
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools